The results are really, really promising because what we have seen is that the efficacy of the drug after four years of follow-up is clear and that the progression free survival there is a reduction of the risk of progression in almost 80% of the patients, in patients treated with ibrutinib, as compared to those who received the control arm which was ofatumumab. This difference is also translated into a benefit in overall survival in these patients and I must say that the toxicity profile is very good. Over the years what we are seeing is that there is a decrease in adverse events at three years and a few patients had serious adverse events such as arterial fibrillation in around 10% of the patients and pneumonia in a low percentage of patients.

So in conclusion we can say that the long follow-up of this trial is confirming the good results that were published at the first interim analysis at nine months in terms of efficacy and toxicity.

Just a quick note, I did see there were some reasons for trial discontinuation. Could you tell us any more about that?

Yes, there was a percentage of discontinuation but half of the patients continued on therapy and the tolerability was quite good.